Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

VT30 topical gel

A topical gel containing VT30, a prodrug of VT10 which is an inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential use in the treatment of cutaneous venous malformations, lymphatic malformations, or mixed venolymphatic malformations associated with PIK3CA or TEK mutations. Upon topical administration, VT30 crosses the skin and is cleaved by naturally occurring enzymes to produce VT10. VT10 binds to and inhibits PIK3CA, blocks PI3K signaling, and suppresses the growth of skin lesions associated with PIK3CA or TEK mutations.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	VT 30 VT-30 VT30

VT30 topical gel

Search NCI's Drug Dictionary